企业QQ
官方微信
Retour à la liste
| Référence | 7014 |
|---|---|
| Statut | CE |
| Echantillon | 30 µl de sang total citraté |
| Quantité | 10 tests |
| Détection | Fluorescence |
| Application | Pour le suivi des antagonistes spécifiques du récepteur plaquettaire à l’ADP (P2Y12) |
| Composition | - Diluant.- PGE1- PGE1 +ADP - Fixateur- Anticorps monoclonal anti VASP-P- Contrôle isotypique négatif- Réactif de révélation-FITC + contre-marqueur plaquettaire (CD61-PE). |
| Date | Nom du document | Taille du fichier | Télécharger |
|---|---|---|---|
| 01/03/2015 | package insert PLT VASP P2Y12 | -478.72 Ko | Télécharger |
| 08/06/2010 | Flyer PLT VASP P2Y12 | -592.82 Ko | Télécharger |
| 01/03/2018 | package insert PLT VASP P2Y12 | -530.45 Ko | Télécharger |
| Auteur | Titre | Année d"édition | Revue |
|---|---|---|---|
| Bagoly Z. et al | How to test the effect of aspirin and clopidogrel in patients on dual antiplatelet therapy? | 2016 | Platelets |
| Danese E. et al | Relationship between pharmacokinetics and pharmacodynamics of clopidogrel in patients undergoing percutaneous coronary intervention: comparison between vasodilator-stimulated phosphoprotein phosphorylation assay and multiple electrode aggregometry | 2016 | J Thromb Haemost. |
| Storey R.F. et al | Platelet Inhibition With Ticagrelor 60 mg Versus 90 mg Twice Daily in the PEGASUS-TIMI 54 Trial | 2016 | J Am Coll Cardiol |
| Rollini F. et al | Impact of timing from blood sampling to pharmacodynamic assessment on measures of platelet reactivity in patients treated with P2Y12 receptor inhibitors | 2016 | Thromb Haemost |
| Umemura K et al | Pharmacokinetics and pharmacodynamics of prasugrel in healthy Japanese subjects | 2016 | Drug Metab Pharmacokinet |
| Franchi F. et al | Pharmacodynamic Comparison of Prasugrel Versus Ticagrelor in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease The OPTIMUS (Optimizing Antiplatelet Therapy in Diabetes Mellitus)-4 Study | 2016 | Circulation |
| Umemura K et al | Pharmacokinetics and pharmacodynamics of prasugrel in healthy Japanese subjects | 2016 | Drug Metab Pharmacokinet |
| Tang N et al. | The relationship between on-clopidogrel platelet reactivity, genotype, and post-percutaneous coronary intervention outcomes in Chinese | 2015 | Scand J Clin Lab Invest |
| Siller-Matula J. M. et al | How to improve the concept of individualised antiplatelet therapy with P2Y12 receptor inhibitors – is an algorithm the answer? | 2015 | Thromb Haemost |
| Aradi D. et al | Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention | 2015 | Eur Heart J |
| Danese E. et al | Relationship between pharmacokinetics and pharmacodynamics of clopidogrel in patients undergoing percutaneous coronary intervention: comparison between vasodilator-stimulated phosphoprotein phosphorylation assay and multiple electrode aggregometry | 2015 | J Thromb Haemost |
| Bonello L. et al | Ticagrelor increases endothelial progenitor cell level compared to clopidogrel in acute coronary syndromes: A prospective study | 2015 | Int J Cardiol |
| Aradi D et al | Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention | 2014 | Eur Heart J. |
| Laine M et al | Ticagrelor versus prasugrel in diabetic patients with an acute coronary syndrome | 2014 | Thromb Haemost |
| Darlington A et al | Pharmacodynamic effects of standard dose prasugrel versus high dose clopidogrel in non-diabetic obese patients with coronary artery | 2014 | Thromb Haemost |
| Patel Y.M. et al | A novel mutation in the P2Y12receptor and a function-reducing polymorphism in PAR-1 in a patient with chronic bleeding | 2014 | J Thromb Haemost |
| Samoš M et al | Clopidogrel resistance in diabetic patient with acute myocardial infarction due to stent thrombosis | 2014 | Am J Emerg Med |
| Wisman P.P et al | Platelet-reactivity tests identify patients at risk of secondary cardiovascular events: a systematic review and | 2014 | J Thromb Haemost |
| Lhermusier T et al | Switching patients from clopidogrel to prasugrel in acute coronary syndrome: impact of the clopidogrel loading dose on platelet reactivity. | 2014 | J Interv Cardiol. |
| Jakubowski JA et al | The influence of body size on the pharmacodynamic and pharmacokinetic response to clopidogrel and prasugrel: A retrospective analysis of the FEATHER study. | 2014 | Thromb Res. |
| Timur AA, et al | Multi-parameter assessment of platelet inhibition and its stability during aspirin and clopidogrel therapy | 2014 | Thromb Res. |
| Grosdidier C et al. | Effect of CYP2C19*2 and *17 Genetic Variants on Platelet Response to Clopidogrel and Prasugrel Maintenance Dose and Relation to Bleeding Complications | 2013 | Am J Cardiol. |
| Gremmel T et al. | Obesity is associated with poor response to clopidogrel and an increased susceptibility to protease activated receptor-1 mediated platelet activation | 2013 | Transl Res. |
| Frelinger A.L et al. | Clopidogrel Pharmacokinetics and Pharmacodynamics Vary Widely Despite Exclusion or Control of Polymorphisms (CYP2C19, ABCB1, PON1), Noncompliance, Diet, Smoking, Co-medications (Including Proton Pump Inhibitors), and Pre-existent Variability in Platelet F | 2013 | J Am Coll Cardiol |
| Gaglia MA et al. | Nuisance and alarming bleeding do not correlate with on-treatment platelet reactivity | 2013 | Cardiovasc Revasc Med. |
| Wun T et al. | A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease | 2013 | J Hematol Oncol. |
| Delavenne X et al. | Investigation of drug–drug interactions between clopidogrel and fluoxetine | 2013 | Fundam. Clin. Pharmacol. |
| Kerneis M et al. | Switching Acute Coronary Syndrome Patients From Prasugrel to Clopidogrel | 2013 | J Am Coll Cardiol Intv |
| Ferreiro JL et al. | Impact of Prasugrel Reload Dosing Regimens on High On-Treatment Platelet Reactivity Rates in Patients on Maintenance Prasugrel Therapy | 2013 | J Am Coll Cardiol |
| Mazur P. et al | Impaired responsiveness to clopidogrel and aspirin in patients with recurrent stent thrombosis following percutaneous intervention for peripheral arterial disease | 2013 | Platelets |
| Nakata T et al | Relationship Between CYP2C19 Loss-of-Function Polymorphism and Platelet Reactivities With Clopidogrel Treatment in Japanese Patients Undergoing Coronary Stent Implantation | 2013 | Circ. J |
| Erlinge D. et al. | Prasugrel 5-mg in the very elderly attenuates platelet inhibition but maintains noninferiority | 2013 | J Am Coll Cardiol |
| Laine M. et al. | Platelet reactivity evaluated with the VASP assay following ticagrelor loading dose in acute coronary syndrome patients undergoing percutaneous coronary intervention | 2013 | Thromb Res. |
| Kim I.S. et al. | Relation between the vasodilator-stimulated phosphoprotein phosphorylation assay and light transmittance aggregometry in | 2013 | Am Heart J |
| El-Halabi MM et al. | CYP2C19 Genetic Polymorphism, Rabeprazole and Esomeprazole Have no Effect on the Anti-Platelet Action of Clopidogrel | 2013 | J Cardiovasc Pharmacol. |
| Fontana P et al. | Tailored Thienopyridine Therapy: No Urgency for CYP2C19 Genotyping | 2013 | J Am Heart Assoc. |
| Gurbel PA et al. | The Influence of Smoking Status on the Pharmacokinetics and Pharmacodynamics of Clopidogrel and Prasugrel: The PARADOX Study | 2013 | J Am Coll Cardiol. |
| Gremmel T et al. | Response to antiplatelet therapy is independent of endogenous thrombin generation potential | 2013 | Thromb Res. |
| Tello-Montoliu M. et al. | Impact of aspirin dose on adenosine diphosphate-mediated platelet activity Results of an in vitro pilot investigation | 2013 | Thromb Haemost |
| Bonello L. et al. | A randomized trial of platelet reactivity monitoring-adjusted clopidogrel therapy versus prasugrel therapy to reduce high on-treatment platelet reactivity | 2013 | Int J Cardiol. |
| Cuisset T. et al | Clinical Implications of Very Low On-Treatment Platelet Reactivity in PatientsTreated With Thienopyridine | 2013 | J Am Coll Cardiol |
| Saucedo JF. et al | Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: Insights from the switching | 2013 | Thromb Haemost |
| Tantry U.S. | Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding | 2013 | J Am Coll Cardiol. |
| Wang X.D et al. | Modified clopidogrel loading dose according to platelet reactivity monitoring in patients carrying ABCB1 variant alleles in patients with clopidogrel resistance | 2012 | Eur J Int Med |
| Kobsar A et al. | The thrombin inhibitors, hirudin und Refludan®, activate the soluble guanylyl cyclase and the cGMP pathway in washed human platelets | 2012 | Thromb Haemost. |
| Jeong YH. et al. | High on-treatment platelet reactivity assessed by various platelet function tests: Is the consensus-defined cutoff of VASP-P platelet reactivity index too low?" | 2012 | J Thromb Haemost |
| Frelinger A.L. et al, | A Randomized, 2-Period, Crossover Design Study to Assess the Effects of Dexlansoprazole, Lansoprazole, Esomeprazole, and Omeprazole on the Steady-State Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy Volunteers | 2012 | J. Am. Coll. Cardiol. |
| Reny J.L. et al. | Influence of the paraoxonase-1 Q192R genetic variant on clopidogrel responsiveness and recurrent cardiovascular events: a systematic review and meta-analysis | 2012 | J Thromb Haemost |
| Tello-Montoliu A.et al. | Pharmacodynamic Effects of Prasugrel Dosing Regimens in Patients on Maintenance Prasugrel Therapy | 2012 | J. Am. Coll. Cardiol. |
| Ferreiro J.L.et al. | Impact of Adjunctive Cilostazol Therapy Versus High Maintenance Dose of Clopidogrel in Suboptimal Responders With Diabetes Mellitus | 2012 | Rev Esp Cardiol. |
| Aradi D et al. | Justification of 150 mg clopidogrel in patients with high on-clopidogrel platelet reactivity | 2012 | Eur J Clin Invest. |
| Yokoi H et al. | Pharmacodynamic assessment of a novel P2Y12 receptor antagonist in Japanese patients with coronary artery disease undergoing elective percutaneous coronary intervention | 2012 | Thromb Res |
| Bonello L. et al | Relationship between post-treatment platelet reactivity and ischemic and bleeding events at one year follow-up in patients receiving prasugrel | 2012 | J Thromb Haemost |
| Liang Y et al | Relation between clopidogrel active metabolite levels and different platelet aggregation methods in patients receiving clopidogrel and aspirin | 2012 | J Thromb Thrombolysis |
| BonelloL. et al | Biological efficacy of a 600 mg loading dose of clopidogrel in ST-elevation myocardial infarction | 2012 | Thromb Haemost. |
| Bonello L. et al | Factors associated with the failure of clopidogrel dose-adjustment according to platelet reactivity monitoring to optimize P2Y12-ADP receptor blockade | 2012 | Thromb Res |
| Erlinge D. et al | Reduction in Platelet Reactivity With Prasugrel 5 mg in Low-Body-Weight Patients Is Noninferior to Prasugrel 10 mg in Higher-Body-Weight Patients | 2012 | J Am Coll Cardiol |
| Suryadevara S. et al | Effects of pioglitazone on platelet P2Y12-mediated signalling in clopidogrel-treated patientswith type 2 diabetes mellitus | 2012 | Thromb Haemost |
| Cuisset T. et al | CYP2C19*2 and *17 Alleles Have a Significant Impact on Platelet Response and Bleeding Risk in Patients Treated With Prasugrel After Acute Coronary Syndrome | 2012 | J Am Coll Cardiol Intv |
| Chang H et al | Modified Diadenosine Tetraphosphates with Dual Specificity for P2Y1 and P2Y12 are Potent Antagonists of ADP-induced Platelet Activation | 2012 | J Thromb Haemost |
| Tello-Montoliu A et al | Impact of renal function on clopidogrel-induced antiplatelet effects in coronary artery disease patients without diabetes mellitus | 2012 | J Thromb Thrombolysis |
| Morel et al | The extent of P2Y12 inhibition by clopidogrel in diabetes mellitus patients with acute coronary syndrome is not related to glycaemic control: roles of white blood cell count and body weight. | 2012 | Thromb Haemost. |
| Yano H et al | Influence of Omeprazole and Famotidine on the Antiplatelet Effects of Clopidogrel in Addition to Aspirin | 2012 | Circ J. |
| KalantziKI et al. | Clopidogrel differentially affects platelet-mediated thrombosis and inflammatoryresponse in patients with acute coronary syndromes | 2011 | J Thromb Haemost. |
| Petrucci G et al. | Prostaglandin E2 Differentially Modulates Human Platelet Function through the Prostanoid EP2 and EP3 Receptors | 2011 | JPET |
| Morel O et al. | Cardiovascular Mortality in Chronic Kidney Disease Patients UndergoingPercutaneous Coronary Intervention Is Mainly Related to Impaired P2Y12 Inhibition by Clopidogrel | 2011 | J. Am. Coll. Cardiol. |
| Ueno M et al. | Functional profile of the platelet P2Y12 receptor signalling pathway in patients with type 2 diabetes mellitus and coronary artery disease | 2011 | Thromb Haemost |
| Angiolillo DJ et al. | Impact of adjunctive cilostazol therapy on platelet function profiles in patients with and without diabetes mellitus on aspirin and clopidogrel therapy | 2011 | Thromb Haemost |
| Freynhofer MK et al. | Multiple electrode aggregometry and vasodilator stimulated phosphoprotein-phosphorylation assay in clinical routine for predictionof postprocedural major adverse cardiovascular events | 2011 | Thromb Haemost |
| Mani H. et al. | Platelet function testing in hirudin and BAPA anticoagulated blood | 2011 | Clin Chem Lab Med |
| Szymezak J. et al. | High on-clopidogrel platelet reactivity: Genotyping can help to optimize antiplatelet treatment | 2011 | Thromb Res |
| Pettersen A. et al. | The influence of CYP 2C19*2 polymorphism on platelet function testing during single antiplatelet treatment with clopidogrel | 2011 | Thrombosis Journal |
| Prüller F. et al. | Low platelet reactivity is recoverd by transfusion ofstored platelets: A healthy volunteer in vivo study | 2011 | J Thromb Haemost |
| Wang XD. et al. | Modifying Clopidogrel Maintenance Doses According to Vasodilator-Stimulated Phosphoprotein Phosphorylation Index Improves Clinical Outcome in Patients With Clopidogrel Resistance | 2011 | Clin. Cardiol. |
| Frelinger A. et al. | Clopidogrel pharmacokinetics and pharmacodynamics vary widely, independent of CYP2C19 polymorphisms, diet, smoking, proton pump inhibitors and other co-medications | 2011 | J. Am. Coll. Cardiol. |
| Angiolillo DJ et al. | Impact of adjunctive cilostazol therapy on platelet function profiles in patients with and without diabetes mellitus on aspirin and clopidogrel therapy | 2011 | Thromb Haemost. |
| Storey RF et al. | Earlier recovery of platelet function after discontinuation of treatment with ticagrelor compared to clopidogrel in patients with high antiplatelet responses | 2011 | J Thromb Haemost |
| Fontana P et al. | Relationship between paraoxonase-1 activity, its Q192R genetic variant and clopidogrel responsiveness in the ADRIE study | 2011 | J Thromb Haemost |
| Fernando H et al. | Randomised Double Blind Placebo Controlled Crossover Study to Determine the Effects of Esomeprazole on Inhibition of Platelet Function by Clopidogrel | 2011 | J Thromb Haemost |
| Bonello L et al. | High On-Treatment Platelet Reactivity After Prasugrel Loading Dose and Cardiovascular Events After Percutaneous Coronary Intervention in Acute Coronary Syndromes | 2011 | J. Am. Coll. Cardiol. |
| Ferreiro JL et al. | Pharmacodynamic evalutation of pentaprazole therapy on cloppidogrel effect | 2011 | Circ Cardiovasc Interv. |
| Ferreiro JL et al. | Impact of Adjunctive Cilostazol Therapy Versus High Maintenance Dose of Clopidogrel in Suboptimal Responders With Diabetes Mellitus | 2011 | Rev Esp Cardiol. |
| Ueno M et al. | Impact of Pentoxifylline on Platelet Function Profiles in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease on Dual Antiplatelet Therapy With Aspirin and Clopidogrel | 2011 | J Am Coll Cardiol Intv |
| Bliden KP et al. | The effect of ticagrelor versus clopidogrel on high on-treatment platelet reactivity: Combined analysis of the ONSET/OFFSET and RESPOND studies | 2011 | Am Heart J. |
| Grdinic A et al. | PCI and clopidogrel: antiplatelet responsiveness and patient characteristics | 2011 | Acta Cardiol. |
| Gaglia MA Jr et al. | Relation of Body Mass Index to On-Treatment (Clopidogrel + Aspirin) Platelet Reactivity | 2011 | Am J Cardiol. |
| Mega J.L et al. | Dosing Clopidogrel Based on CYP2C19 Genotype and the Effect on Platelet Reactivity in Patients With Stable Cardiovascular Disease | 2011 | JAMA |
| Tsoumani ME | Antiplatelet Efficacy of Long-Term Treatment With Clopidogrel Besylate in Patients With a History of Acute Coronary Syndrome: Comparison With Clopidogrel Hydrogen Sulfate | 2011 | Angiology |
| MotovskaZ et al. | Optimal pretreatment timing for high load dosing (600 mg) of clopidogrel before planned percutaneous coronary intervention for maximal antiplatelet effectiveness | 2010 | Int J Cardiol. |
| PalmeriniT. et al, | A randomised study comparing the antiplatelet and antinflammatory effect of clopidogrel 150 mg/day versus 75 mg/day in patients with ST-segment elevation acute myocardial infarction and poor responsiveness to clopidogrel: Results from the DOUBLE study | 2010 | Thromb Res |
| Bonello L et al. | Impact of loading dose adjustment on platelet reactivity in homozygotes of the 2C19 2* loss of function polymorphism | 2010 | Int J cardiol. |
| Bonello L et al. | Impact of P2Y12-ADP receptor polymorphism on the efficacy of clopidogrel dose-adjustment according to platelet reactivity monitoring in coronary artery disease patients | 2010 | Thromb Res. |
| von Beckerath N et al. | Assessment of platelet response to clopidogrel with multiple electrode aggregometry, the VerifyNow P2Y12 analyzer and platelet vasodilator-stimulated phosphoprotein flow cytometry | 2010 | Blood Coagulation and Fibrinolysis |
| Gurbel PA et al. | The Effect of Elinogrel on High Platelet Reactivity During Dual Antiplatelet Therapy and the Relation to CYP 2C19*2 Genotype:First Experience in Patients | 2010 | J Thromb Haemost. |
| Bellemain-Appaix A et al. | Slow Response to Clopidogrel Predicts Low Response | 2010 | J. Am. Coll. Cardiol. |
| Metzmer H et al. | Premature preoperative discontinuation of antiplatelet drug therapy in cardiovascular risk patients: a preliminary study on the role of P2Y12 receptor monitoring | 2010 | Eur J Anaesthesiol. |
| Cuisset T et al. | Clopidogrel response: Head-to-head comparison of different platelet assays to identify clopidogrel non responder patients after coronary stenting | 2010 | Archives of Cardiovascular Disease |
| Gurbel PAet al. | Response to Ticagrelor in Clopidogrel Nonresponders and Responders and Effect of Switching Therapies. The RESPOND Study | 2010 | Circulation |
| Small DS et al. | Pharmacodynamics and Pharmacokinetics of Single Doses of Prasugrel 30 mg and Clopidogrel 300 mg in Healthy Chinese and White Volunteers: An Open-Label Trial | 2010 | Clin Ther. |
| Flierl U et al. | The novel P2Y12 antagonist AZD6140 rapidly and reversibly reduces platelet activation in diabetic rats | 2010 | Thromb Res |
| Bouman HJ et al. | Which platelet function test is suitable to monitor clopidogrel responsiveness? A pharmacokinetic analysis on the active metabolite of clopidogrel | 2010 | J Thromb Haemost. |
| Gajos G et al. | Effects of Polyunsaturated Omega-3 Fatty Acids on Responsiveness to Dual Antiplatelet Therapy in Patients UndergoingPercutaneous Coronary Intervention | 2010 | J. Am. Coll. Cardiol. |
| El Ghannudi S | Impact of P2Y12 Inhibition by Clopidogrel on Cardiovascular Mortality in Unselected Patients Treated by Percutaneous Coronary Angioplasty | 2010 | J Am Coll Cardiol Intv |
| Bonello L et al. | Clopidogrel Loading Dose Adjustment According to Platelet Reactivity Monitoring in Patients Carrying the 2C19 2* Loss of Function Polymorphism | 2010 | J. Am. Coll. Cardiol. |
| Delavenne Xet al. | Is there really a relationship between the plasma concentration of the active metabolite of clopidogrel and the results of platelet function tests? | 2010 | J Thromb Haemost. |
| Aradi D et al. | Comparison of conventional aggregomerty with VASP for monitoring P2Y12-specifc platelet inhibition | 2010 | Platelets |
| Zighetti ML et al. | Usefulness of a flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of patients with genetic defects of the platelet P2y12 receptor for ADP | 2010 | J Thromb Haemost. |
| Bonello L et al. | Consensus and Future Directions on the Definition of High On-Treatment Platelet Reactivity to Adenosine Diphosphate | 2010 | J. Am Coll Cardiol. |
| Storey RF et al. | Inhibitory Effects of Ticagrelor Compared With Clopidogrel on Platelet Function in Patients With Acute Coronary Syndromes The PLATO (PLATelet inhibition and patient Outcomes) PLATELET Substudy | 2010 | J. Am. Coll. Cardiol. |
| Angiolillo DJ et al. | Increased Platelet Inhibition After Switching From Maintenance Clopidogrel to Prasugrel in Patients With Acute Coronary Syndromes Results of the SWAP (SWitching Anti Platelet) Study | 2010 | J. Am. Coll. Cardiol. |
| Bonello L et al. | Level of P2Y12-ADP receptor blockade during percutaneous coronary intervention predicts the extent of endothelial injury,assessed by CEC measurement | 2010 | J. Am. Coll. Cardiol. |
| Bjellanda TW et al. | Antiplatelet effect of clopidogrel is reduced in patients treated with therapeutic hypothermia after cardiac arrest | 2010 | Resuscitation |
| Fu Q et al. | Comparison of platelet P2Y12 ADP receptor mediated pathway inhibition in triple versus dual antiplatelet therapy as assessed by VASP phosphorylation in japanese patients undergoing coronary stenting | 2010 | Int Heart J. |
| Fontana P et al. | Clinical predictors of dual aspirin and clopidogrel poor responsiveness in stable cardiovascular patients from the ADRIE study | 2010 | J Thromb Haemost. |
| Ferreiro JL et al. | Pharmacodynamic effects of concomitant versus stagerred clopidogrel and omeprazole intake | 2010 | Circ Cardiovasc Interv. |
| Tantry U et al. | First Analysis of the Relation Between CYP2C19 Genotype and Pharmacodynamics in Patients Treated With Ticagrelor Versus Clopidogrel. The ONSET/OFFSET and RESPOND Genotype Studies | 2010 | Circ Cardiovasc Genet. |
| Osmancik P et al. | A comparison of the VASP index between patients with hemodynamically complicated and uncomplicated acute myocardial infarction" | 2010 | Catheter Cardiovasc Interv. |
| Bonello L et al. | Tailored Clopidogrel Loading Dose According to Platelet Reactivity Monitoring to Prevent Acute and Subacute Stent Thrombosis | 2009 | Am J Cardiol. |
| Lortie E. et al. | Clopidogrel induces an acute hemostatic deficit and increases intra abdominal bleeding in rabbits | 2009 | Thromb Res |
| Siller-Matula JM et al. | The effect of antiplatelet drugs clopidogrel and aspirin is less immediately after stent implantation | 2009 | Thromb Res |
| Bonello L et al. | Emergence of the Concept of Platelet Reactivity Monitoring of Response to Thienopyridines | 2009 | Heart |
| Hogberg C. et al . | Mild hypothermia does not attenuate platelet aggregation and may even increase ADP-stimulated platelet aggregation after clopidogrel treatment | 2009 | Thrombosis Journal |
| Cuisset T et al. | Relationship between aspirin and clopidogrel responses in acute coronary syndrome and clinical predictors of non response | 2009 | Thromb Res. |
| Varenhorst C et al. | Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease | 2009 | Eur Heart J |
| MotovskaZ et al. | High loading dose of clopidogrel is unable to satisfactorily inhibit platelet reactivity in patients with glycoprotein IIIA gene polymorphism: a genetic substudy of PRAGUE-8 trial | 2009 | Blood Coagul Fibrinolysis |
| Michelson A. et al | Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial | 2009 | European Heart Journal |
| Cuisset T et al. | Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non ST-elevation acute coronay syndrome | 2009 | EuroIntervention |
| Aleil B. et al. | CYP2C19*2 polymorphism is not the sole determinant of the response to clopidogrel: implications for its monitoring | 2009 | J Thromb Haemost |
| Siller-Matula JM et al. | Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel | 2009 | Am Heart J |
| Cuisset T et al. | Comparison of Omeprazole and Pantoprazole Influence on a High 150-mg Clopidogrel Maintenance Dose | 2009 | J. Am. Coll. Cardiol. |
| Alström U et al. | Platelet inhibition assessed with VerifyNow, flow cytometry and PlateletMapping in patients undergoing heart surgery | 2009 | Thromb Res |
| Siller-Matula JM et al. | Cross validation of the Multiple Electrode Aggregometry | 2009 | Thromb Haemost. |
| Gremmel T et al. | Comparison of methods to evaluate clopidogrel-mediated platelet inhibition after percutaneous intervention with stent implantation | 2009 | Thromb Haemost. |
| James S et al. | Comparison of ticagrelor, the first reversible oral P2Y12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial | 2009 | Am Heart J |
| Gurbel PA and Tantry U. | Selecting Optimal Antiplatelet Therapy Based on Platelet Function Monitoring in Patients With Coronary Artery Disease | 2009 | Curr Treat Op Cardio Med |
| Frere C et al. | CYP2C19*17 Allele is associated with Better Platelet Response to Clopidogrel in patients admitted for Non-ST Acute Coronary Syndrome | 2009 | J Thromb Haemost. |
| MotovskaZ et al. | Clopidogrel resistance Live" - the risk of stent thrombosis should be evaluated before procedures | 2009 | Thrombosis J |
| MotovskaZ et al. | Factors Influencing Clopidogrel Efficacy in Patients With Stable Coronary Artery Disease Undergoing Elective Percutaneous Coronary Intervention: Statin"s Advantage and the Smoking | 2009 | J Cardiovasc Pharmacol |
| Wallentin L et al. | Prasugrel achieves greater and faster P2Y12 receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease | 2008 | European Heart Journal |
| Sbrana S et al. | Relationships between optical aggregometry (type born) and flow cytometry in evaluating ADP-induced platelet activation | 2008 | Cytometry Part B |
| Gilard M. et al. | Influence of Omeprazole on the Antiplatelet Action of Clopidogrel Associated With Aspirin: The Randomized, Double-Blind OCLA (Omeprazole CLopidogrel Aspirin) Study | 2008 | J. Am. Coll. Cardiol. |
| Gurbel PA et al. | Omeprazole A Possible New Candidate Influencing the Antiplatelet Effect of Clopidogrel | 2008 | J. Am. Coll. Cardiol. |
| Frere C et al. | Effect of Cytochrome P450 Polymorphisms on Platelet Reactivity After Treatment With Clopidogrel in Acute Coronary Syndrome | 2008 | Am J Cardiol. |
| Angiolillo DJ et al. | Functional Effects of High Clopidogrel Maintenance Dosing in Patients With Inadequate Platelet Inhibition onStandard Dose Treatment | 2008 | Am J Cardiol. |
| Bonello L et al. | Adjusted Clopidogrel Loading Doses According to VASP Phosphorylation Index Decrease Rate of Major Adverse Cardiovascular Events in Patients With Clopidogrel Resistance: A Multicentre Randomized Prospective Study | 2008 | J. Am. Coll. Cardiol. |
| Jakubowski J et al. | A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry | 2008 | Thromb Haemost. |
| Yano Y et al. | Determinants of thrombin generation,fibrinolytic activity, and endothelial dysfunctionin dual-antiplatelet therapy: involvement of factors other than platelet aggregability in Virchow’s triad | 2008 | Eur Heart J. |
| Umemura K et al, | The common gene variants of CYP2C19 affect pharmacokinetics and pharmacodynamics to an active metabolite of clopidogrel in healthy subjects | 2008 | J Thromb Haemost |
| Bonello L et al, | A threshold of platelet reactivity for ischaemic events? | 2008 | Eur Heart J. |
| Bonello L et al, | Two strategies of clopidogrel loading dose to decrease the frequency of clopidogrel resistance in patients undergoing percutaneous coronary intervention | 2008 | Thromb Res |
| Michelson A et al. | P2Y12 Antagonism: Promises and Challenges | 2008 | ATVB |
| Angiolillo DJ et al. | A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study | 2008 | Eur Heart J. |
| Schäfer A et al. | ADP-induced platelet aggregation frequently fails to detect impaired clopidogrel-responsiveness in patients with coronary artery disease compared to a P2Y12-specific assay | 2008 | Thromb Haemost |
| Siller-Matula JM et al. | Calcium-Channel Blockers Reduce the Antiplatelet Effect of Clopidogrel | 2008 | J. Am. Coll. Cardiol. |
| Morel O et al. | Residual prothrombotic status in low responder patients to clopidogrel identified by Vasodilator-Stimulated Phosphoprotein Phosphorylation (VASP) analysis? | 2008 | Thromb Haemost |
| Djukanovic N. et al. | Thienopyridine Resistance Among Patients Undergoing Intracoronary Stent Implantation and Treated With Dual Antiplatelet Therapy: Assessment of Some Modifying Factors | 2008 | J Pharmacol Sci |
| De Miguel A et al. | Clinical implications of clopidogrel resistance | 2008 | Thromb Haemost. |
| WeberAA et al. | Methods to Evaluate the Pharmacology of Oral Antiplatelet Drugs | 2008 | Herz |
| Aleil B al. | Clopidogrel 150 mg/day to Overcome Low Responsiveness in Patients Undergoing Elective Percutaneous Coronary Intervention" | 2008 | J Am Coll Cardiol Intv |
| Erlinge D et al. | Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo | 2008 | J. Am. Coll. Cardiol. |
| Cayla G et al. | Flow cytometric assessment of vasodilator-stimulated phosphoprotein: Prognostic value of recurrent cardiovascular events after acute coronary syndromes | 2008 | Arch Cardiovasc Dis. |
| Aleil B et al. | Ticlopidine could be an alternative therapy in the case of pharmacological resistance to clopidogrel: a report of three cases | 2007 | J Thromb Haemost |
| Angiolilo DJ et al. | Randomized comparison of a high clopidogrel maintenance dose in patients with Diabetis mellitus and coronary artery disease | 2007 | Circulation |
| van Werkum et al. | The flow cytometric VASP assay can be used to determined the effectiveness of clopidogrel in patients treatedwith Abciximab | 2007 | J Thromb Haemost |
| Cuisset T et al. | Lack of association between the 807C/T polymorphism of glycoprotein Ia gene and post-treatment platelet reactivity after aspirin and clopidogrel in patients with acute coronary syndrome | 2007 | Thromb Haemost. |
| Mueller Tet al. | Utility of whole blood impedance aggregometry for the assessment of clopidogrel action using the novel Multiplate® analyzer -comparison with two flow cytometric methods" | 2007 | Thromb Res |
| Cuisset T. et al. | Role of the T744C polymorphism of the P2Y12 gene on platelet response to a 600-mg loading dose of clopidogrel in 597 patients with non-ST-segment elevation acute coronary syndrome | 2007 | Thromb Res |
| Bonello L et al. | VASP phosphorylation analysis prior to percutaneous coronary intervention for exclusion of post-procedural major adverse cardiovascular events | 2007 | J Thromb Haemost |
| Cattaneo M et al. | Platelet P2 receptors: old and new targets for antithrombotic drugs | 2007 | Cardiovascular Therapy |
| Gurbel PA et al. | Assessment of clopidogrel responsiveness : measurements of maximum platelet agreggation, final platelet agreggation and their correlation with Vasodilator stimulated phosphoprotein in resistant patients | 2007 | Thromb Res |
| Schumacher WA et al. | Biomarker optimization to track antithrombotic and hemostatic effects of clopidogrel | 2007 | J Pharmacol Exp Ther. |
| De Gaetano and Cerletti. | Platelet function, antiplatelet therapy and clinicla outcomes : to test or not to test ? | 2007 | J Thromb Haemost |
| Paniccia R et al. | Different methodologies for evaluating the effect of clopidogrel on platelet function in high isk coronary artery disease patients | 2007 | J Thromb Haemost |
| Dropinski et al. | The additive antiplatelet action of clopidogrel in patients with coronary artery disease treated with aspirin | 2007 | Thromb Haemost. |
| Fontana P et al. | Biological effect of increased maintenance dose of clopidogrel in cardiovascular outpatients and influence of the cytochrome P450 2C19*2 allele on clopicogrel responsiveness | 2007 | Thromb Haemost. |
| Morel O et al. | Impaired platelet responsiveness to clopidogrel identified by flow cytometric VASP phosphorylation in patients with subacute stent thrombosis | 2007 | Thromb Haemost. |
| Frere C et al. | ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome | 2007 | Thromb Haemost. |
| Gurbel PA et al. | Platelet function monitoring in patients with coronary artery disease | 2007 | JACC |
| Blindt R et al. | The Significance of Vasodilator-Stimulated Phosphoprotein for Risk Stratification of Stent Thrombosis | 2007 | Thromb Haemost. |
| Eli Lev et al. | Effect of caffeine on platelet inhibition by clopidogrel in healthy subjects and patients with coronary artery disease | 2007 | Am Heart J |
| Schäfer A et al. | Late thrombosis of a drug-eluting stent during combined anti-platelet therapy in a clopidogrel nonresponsive diabetic patient: Shall we routinely test platelet function ? | 2007 | Thromb Haemost. |
| Wiviott SD et al. | Prasugrel Compared With High Loading- and Maintenance-Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention | 2007 | Circulation |
| Montalescot G et al. | A randomized comparison of high clopidogrel loading doses in patients with non -ST-Segment elevation Acute coronary syndromes | 2006 | JACC |
| Gilart M.et al. | Influence of omeprazol on the anti platelet action of clopidogrel associated to aspirin | 2006 | J Thromb Haemost |
| Bura A et al. | Role of the P2Y12 gene polymorphism in the platelet responsiveness to clopidogrel in healty subjects | 2006 | J Thromb Haemost |
| Hulot JS et al. | Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects | 2006 | Blood |
| Cauwenberghs et al. | Plasma ectonucleotidases prevent desensitization of purinergic receptors in stored platelets: importance for platelet activity during thrombus formation | 2006 | Transfusion |
| Pampuch et al. | Comparison of VASP phosphorylation assay to light transmission aggregometry in assessing inhibition of the platelet ADP P2Y12 receptor | 2006 | Thromb Haemost. |
| Gurbel PA and Tantry U | Drug insight : clopidogrel responsiveness | 2006 | Nat Clin Pract Cardiovasc Med |
| Aleil B et al. | Flow cytometry analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases | 2005 | J Thromb Haemost |
| Aleil B et al. | High stability of blood samples for flowcytometric analysis of VASP phosphorylation to measure the clopidogrel responsiveness in patients with coronary artery disease | 2005 | Thromb Haemost. |
| AleilB and Gachet C | Inter-individual variability in the response to clopidogrel | 2005 | Archives des Maladies du Coeur et des Vaisseaux |
| Gurbel PA et al. | Clopidogrel Effect on Platelet REactivity in Patients With Stent Thrombosis, Results of the CREST Study | 2005 | J Am Coll Cardiol |
| Barragan P et al. | Resistance to thienopyridines : clinical detection of coronary stent thrombosis by monitoring of vasodilatator-stimulated phosphoprotein phosphorylation | 2003 | Cathet Cardiovasc Intervent |
| Titre | Référence |
|---|---|
| PLATELET GpIIb/IIIa Occupancy | 7001 |
| CY-QUANT VASP/P2Y12 | 7502 |
Retour à la liste
SouthernBiotech/Goat Anti-Human Lambda-Alexa Fluor® 555/2070-32/1.0 mg
vectorlabs/Biotinylated Aleuria Aurantia Lectin (AAL)/B-1395/1 mg
vectorlabs/VECTASTAIN® Elite® ABC-HRP Kit (Peroxidase, Mouse IgG)/PK-6102/1 kit
vectorlabs/VECTASTAIN® Elite® ABC-HRP Kit (Peroxidase, Universal)/PK-6200/1 kit
vectorlabs/Unconjugated Musa Paradisiaca (Banana) Lectin (BanLec)/L-1410/5 mg
GiottoBiotech/Calmodulin N60D/5 mg/G02CLM60cn